The Asian Health Foundation research study, ENUMERATE (ENtecavir Utilization, Management and Efficacy in the United States: A MulTi-cEnter study), is currently underway. Funded by Bristol Myers Squibb, the study seeks to identify risk factors associated with the development of hepatocellular carcinoma (HCC) in chronic hepatitis B, and to evaluate the efficacy of entecavir and its impact on the development of HCC in these patents. Dr. Joseph Ahn is the Principal Investigator for this study.

Site enrollment and review of patient records has been initiated with AHF Advisory Board Members who are participating in this multi-center study. AHF hopes to enroll a total of 800 patients into this retrospective chart review of hepatitis B patients who have been treated with entecavir. Enrollment of patients is limited to those with full baseline data set of demographics, ALT, and HBV DNA, and at least one year of on-treatment ALT, HBV DNA, and clinical follow up. For more information, please contact

6th Annual AHF Content Development Meeting

DOWNLOAD the AHF 2012 Dinner Meeting Series Slide Deck - New Insights into Hepatitis B Diagnosis and Treatment

*For reference only - there is no CME / CE credit available


To donate to the AHF, Please click here
to be redirected to our PayPal Account.




Strategies & Solutions
for Hepatitis B Screening,
Testing, Linkage to Care,
& Treatment


© Copyright 2016 Asian Health Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the AHF terms of use and privacy statement.